A Prospective Study to Follow Patients with Plasma Cell Disorders at Peking University First Hospital

What this Trial Is About

Researchers are establishing a prospective group of patients with plasma cell disorders PCDs to better understand these conditions and their treatments. This study focuses on various PCDs including multiple myeloma, amyloidosis, and other related disorders. It aims to explore how minimal residual disease MRD status relates to patient prognosis and investigate the role of the tumor microenvironment TME in the diseases development and progression. Patients with confirmed PCDs who are hospitalized and willing to participate will be followed over time. Biological samples such as peripheral blood, bone marrow aspirate, and urine will be collected before and after treatment to support future research. The study does not involve any intervention and participants will be regularly assessed at baseline, then at 1, 3, 6, and 12 months after treatment, followed by yearly visits. During the study, clinical and laboratory data along with biological samples will be gathered to analyze disease features and treatment responses. Follow-up visits will monitor patient progress and outcomes for up to ten years. The main outcome is to maintain a comprehensive cohort and understand the relationship between MRD and prognosis in PCD patients, while also supporting further studies on tumor clone evolution and disease mechanisms.

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH